Xenova Creates New Subsidiary

8 June 1997

UK company Xenova has created a new subsidiary, Xenova Discovery, whichis to be headed by David Oxlade as chief executive. He joins the firm from Syva, a division of Behring Diagnostics.

The staff, business and assets of Xenova's discovery division have been handed over to Xenova Discovery, which will assume responsibility for discovery-related management of the group's existing collaborative agreements. Michael Moore, formerly research director of the division, is appointed research director of the new company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight